Johnson & Johnson Stock

$156.90

0.50% day before yesterday

NYSE, Jul 11, 10:08 pm CET

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Johnson & Johnson Stock price

$156.90

+11.69 8.05% 5Y

NYSE, Closing price Fri, Jul 11 2025

-0.79 0.50%

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$377.5b

Enterprise Value

$391.0b

Net debt

$13.5b

Cash

$38.8b

Shares outstanding

2.4b

Valuation (TTM | estimate)

P/E

17.5 | 14.6

P/S

4.2 | 4.1

EV/Sales

4.4 | 4.2

EV/FCF

19.2

P/B

4.8

Dividends

DPS

$4.91

Yield 1Y | 5Y

3.1% | 2.8%

Growth 1Y | 5Y

4.5% | 5.5%

Payout 1Y | 3Y

84.8% | 53.6%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$89.3b | $92.4b

EBITDA

$30.7b | $34.0b

EBIT

$23.4b | $30.1b

Net Income

$21.8b | $25.8b

Free Cash Flow

$20.4b

Growth (TTM | estimate)

Revenue

4.3% | 4.0%

EBITDA

-3.2% | 10.3%

EBIT

-3.6% | 28.0%

Net Income

-43.3% | 83.6%

Free Cash Flow

8.9%

Financial Health

Equity Ratio

39.7%

Return on Equity

19.7%

ROCE

17.1%

ROIC

13.6%

Debt/Equity

0.7

EPS

$9.0

FCF per Share

$8.5

Short interest

0.7%

Employees

138k

Rev per Employee

$640.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

29 Analysts have issued a Johnson & Johnson forecast:

13x Buy

45%

16x Hold

55%

More details on Analyst Estimates Including Price Targets

29 Analysts have issued a Johnson & Johnson forecast:

Buy

45%

Hold

55%

Analyst Estimates with Stock Price Targets

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	89,331 89,331	4% 4% 100%
- Direct Costs	28,281 28,281	9% 9% 32%
Gross Profit	61,050 61,050	2% 2% 68%
- Selling and Administrative Expenses	22,724 22,724	4% 4% 25%
- Research and Development Expense	16,915 16,915	11% 11% 19%
EBITDA	30,668 30,668	3% 3% 34%
- Depreciation and Amortization	7,296 7,296	2% 2% 8%
EBIT (Operating Income) EBIT	23,372 23,372	4% 4% 26%
Net Profit	21,810 21,810	43% 43% 24%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Johnson & Johnson Stock News

Neutral

Barrons

●

about 2 hours ago

Wells Fargo, Citi, Netflix, J&J, and More Stocks to Watch This Week

Financials make up half of the 38 S&P 500 companies slated to report quarterly results this week. The week's big economic news will be the consumer price index for June.

Positive

The Motley Fool

●

about 10 hours ago

This Stock Has Increased 4,720%: Here's Why It's Still a Buy

Time is one of investors' greatest allies. With enough patience, even a relatively small sum of money invested in an excellent company can yield substantial returns, especially when dividends are reinvested.

Positive

Seeking Alpha

●

2 days ago

Mar Vista U.S. Quality Q2 2025 Top Contributors And Detractors

Microsoft, Broadcom, and Oracle were among the portfolio's top contributors for the quarter. Alternatively, Apple, Johnson & Johnson, and Berkshire Hathaway detracted from performance. Microsoft shares rebounded in calendar Q2 following a strong fiscal Q3 2025 (March quarter), driven by accelerating demand for AI-related Azure services.

More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office	United States
CEO	Joaquin Duato
Employees	138,100
Founded	1887
Website	www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now